Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company centered on nitric oxide (NO) technologies, and its news flow reflects both commercial execution and clinical development. Company announcements frequently highlight progress with the LungFit PH system, a cylinder-free NO generator and delivery device approved for treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Investors can follow updates on U.S. hospital adoption, international distribution agreements, regulatory milestones, and quality certifications related to this platform.
News items also cover Beyond Air’s broader LungFit pipeline, including clinical trials evaluating higher-concentration NO for severe lung infections such as viral community-acquired pneumonia and nontuberculous mycobacteria. These stories often discuss regulatory submissions, design patents for next-generation devices, and participation in medical and industry conferences.
On the biopharmaceutical side, Beyond Air and its affiliates generate news about oncology and neurology programs. Beyond Cancer, Ltd. reports early-stage clinical data and preclinical work using ultra-high concentration NO for solid tumors, while NeuroNOS communications describe small-molecule nNOS inhibitors, preclinical findings in Autism Spectrum Disorder and brain cancers, and U.S. FDA Orphan Drug Designations for glioblastoma and Phelan-McDermid Syndrome. Transactions such as the agreement for XTL Biopharmaceuticals to acquire a majority stake in NeuroNOS are also covered.
Capital markets and corporate governance updates are another recurring theme, including private placements, warrant exercises, promissory notes, equity purchase agreements, reverse stock splits, and leadership changes. For investors and analysts tracking XAIR, this news page provides a centralized view of commercial rollouts, clinical milestones, financing activity, and strategic partnerships that shape the company’s nitric oxide-focused portfolio.
Summary not available.
Beyond Cancer, Ltd., an affiliate of Beyond Air (NASDAQ: XAIR), has presented new promising data at the AACR Annual Meeting 2023 supporting its ultra-high concentration nitric oxide (UNO) therapy for treating solid tumors. Key findings from in vivo studies indicate that UNO provides significant survival benefits in aggressive 4T1 breast cancer models, outperforming checkpoint inhibitors like anti-CTLA-4 and anti-PD-1. Moreover, UNO demonstrated a dose-dependent increase in mPD-L1 expression, suggesting its potential to enhance tumor sensitivity to immunotherapy. The ongoing Phase 1 study is expanding to multiple sites in Israel to diversify patient enrollment and expedite results. The data highlight the possibility of UNO as an effective treatment option with limited toxicity for difficult-to-treat cancer types.
Additional trials are anticipated throughout 2023.
Beyond Air announces the appointment of Dr. Jeff Myers as Chief Medical Officer, effective March 27, 2023, bringing nearly 15 years of executive experience in biopharmaceuticals. Dr. Andrew Colin will transition to Senior Medical Director Global Clinical Leadership, ensuring continuity. Dr. Myers, a former cardiothoracic surgeon, aims to advance Beyond Air's LungFit platform, which recently gained FDA approval for treating persistent pulmonary hypertension in newborns. The company also granted Dr. Myers stock options and restricted stock units to incentivize his role. Beyond Air focuses on developing inhaled nitric oxide therapies for respiratory conditions and solid tumors.
Beyond Cancer, Ltd., an affiliate of Beyond Air (NASDAQ: XAIR), has announced its poster presentations at the AACR Annual Meeting 2023, scheduled for April 14-19 in Orlando, Florida.
Two posters will be presented by Hila Confino, PhD, Chief Scientific Officer:
- Title: Intratumoral administration of ultra-high concentration nitric oxide (UNO) is more efficacious than anti-PD1 therapy in 4T1 tumor-bearing mice.
- Title: Short-term exposure of cancer cells to UNO induces PD-L1 upregulation.
Both presentations will occur on April 19, highlighting new immunotherapeutic approaches using nitric oxide.
Beyond Air, Inc. (NASDAQ: XAIR) announced that its CEO, Steve Lisi, will participate in two investor conferences in March 2023. The first event is the 35th Annual Roth Conference from March 12-14, where Lisi will engage in a fireside chat on March 13 in Laguna Niguel, CA. The second event is the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, featuring a presentation by Lisi on March 15 at 9:20 AM ET in a virtual format. Beyond Air focuses on developing inhaled nitric oxide treatments for respiratory conditions and is advancing its LungFit systems in clinical trials for severe lung infections.
Beyond Air, Inc. (NASDAQ: XAIR) announced its financial results for Q3 ended December 31, 2022, reporting a GAAP net loss of $13.8 million or ($0.43) per share, compared to $7.7 million or ($0.29) per share last year. The company is advancing the limited launch of its LungFit® PH for treating hypoxic respiratory failure, expecting initial sales in the March quarter. Research expenses rose to $5.0 million due to heightened operational costs. The firm also presented promising data on its ultra-high concentration nitric oxide therapy for solid tumors, showcasing significant survival improvements in pre-clinical studies. Cash and equivalents stand at $63.2 million.
Beyond Cancer has appointed Gavin Choy, PharmD as Chief Operating Officer, bringing over 20 years of experience in pharmaceutical and biotechnology sectors. Dr. Choy will oversee clinical trials for ultra-high concentration nitric oxide (UNO), aimed at treating solid tumors. His prior successes include leading clinical development for multiple drug applications across various countries. Beyond Cancer focuses on innovative therapies to enhance treatment options for oncology patients. The company’s UNO therapy has shown potential in preclinical studies to prevent relapse and reduce tumor metastases.
Beyond Cancer, Ltd., an affiliate of Beyond Air (NASDAQ: XAIR), has entered a sponsored research agreement with Stanford School of Medicine to advance its ultra-high concentration nitric oxide (UNO) therapy for solid tumors. Dr. Frederick M. Dirbas and Dr. Mark D. Pegram have been appointed to the Scientific Advisory Board (SAB), with Dirbas serving as Chair. This collaboration aims to influence clinical development and regulatory submissions for UNO therapy, which is being studied for its potential to enhance cancer treatment efficacy and safety. The first human study for UNO is underway, focusing on solid tumors.
Beyond Air, a medical device and biopharmaceutical company, will report its financial results for the third fiscal quarter ending December 31, 2022, on February 9, 2023. The announcement comes as the company focuses on developing inhaled nitric oxide for treating respiratory conditions and ultra-high concentration nitric oxide for solid tumors through its affiliate, Beyond Cancer. A conference call will be held at 4:30 PM ET the same day to discuss these results. Beyond Air has received FDA approval for its LungFit PH system, targeting persistent pulmonary hypertension of the newborn, and is advancing other clinical trials.
Beyond Cancer, an affiliate of Beyond Air (NASDAQ: XAIR), published pre-clinical data showing that ultra-high concentrations of nitric oxide (UNO) significantly enhance immune responses against solid tumors. The study indicated that UNO-treated mice exhibited improved survival rates and reduced tumor metastasis. These findings were detailed in the journal Cancer Cell International. The research supports the potential of UNO as an innovative treatment for solid tumors, with a first-in-human Phase 1 trial already in progress.